MétaCan
ENFR
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

Export CSVExport JSONAPI query

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Topic
Advanced Breast Cancer Therapies
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

898 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
898 works in the cohort · of 4,299,418page 5 of 18

Labels cover 3 of 898 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 898 of 898 works in this cohort. Predictions are machine_predicted_unvalidated teacher distillation outputs. Candidate is the union; consensus is the intersection.

affunlabeled
Abstract GS4-01: Ten-year results from NRG Oncology/NSABP B-42: A randomized, double-blinded, placebo-controlled clinical trial of extended adjuvant endocrine therapy with letrozole (L) in postmenopausal women with hormone-receptor+ breast cancer (BC) who have completed previous adjuvant therapy with an aromatase inhibitor (AI)
Eleftherios P. Mamounas, Hanna Bandos, Barry C. Lembersky, Jeon Hyeon Jeong, Charles E. Geyer, Priya Rastogi +14 more
2020· article· en· Cancer Research· Medicine
distilled prediction:candidate · metaepi_narrow+research_integrityconsensus · none
15
citations
affunlabeled
Abstract P5-21-03: Palbociclib (PAL) + letrozole (LET) as first-line therapy in estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC): Efficacy and safety updates with longer follow-up across patient subgroups
HS Rugo, RS Finn, Véronique Dièras, Johannes Ettl, Oleg Lipatov, Anil A. Joy +8 more
2018· article· en· Cancer Research· Medicine
distilled prediction:candidate · metaepi_narrow+insufficient_payloadconsensus · none
15
citations
affno abstractunlabeled
Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from a two-part, multicentre, single-arm, phase 2a study
Santiago Escrivá-de-Romaní, Juan Miguel Cejalvo, Emilio Alba, Jennifer Friedmann, Álvaro Rodríguez-Lescure, Marie-France Savard +13 more
2025· article· en· The Lancet Oncology· Medicine
distilled prediction:candidate · metaepi_narrowconsensus · none
14
citations
affunlabeled
Abstract PD2-07: Alpelisib + letrozole in patients with <i>PIK3CA-</i>mutated, hormone-receptor positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) previously treated with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + fulvestrant: BYLieve study results
Hope S. Rugo, Florence Lerebours, Dejan Juric, Nicholas C. Turner, Stephen Chia, Pamela Drullinsky +6 more
2021· article· en· Cancer Research· Medicine
distilled prediction:candidate · metaepi_narrow+research_integrity+insufficient_payloadconsensus · none
14
citations
affunlabeled
Long-term safety of inavolisib (GDC-0077) in an ongoing phase 1/1b study evaluating monotherapy and in combination (combo) with palbociclib and/or endocrine therapy in patients (pts) with <i>PIK3CA</i>-mutated, hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (BC).
Philippe L. Bédard, Melissa Accordino, Andrés Cervantes, Valentina Gambardella, Erika Hamilton, Antoîne Italiano +13 more
2022· article· en· Journal of Clinical Oncology· Medicine
distilled prediction:candidate · noneconsensus · none
14
citations
affunlabeled
Abstract OT2-11-05: SERENA-6: A Phase III study to assess the efficacy and safety of AZD9833 (camizestrant) compared with aromatase inhibitors when given in combination with palbociclib or abemaciclib in patients with HR+/HER2- metastatic breast cancer with detectable <i>ESR1</i>m who have not experienced disease progression on first-line therapy
François‐Clément Bidard, Kevin Kalinsky, Massimo Cristofanilli, Giampaolo Bianchini, Stephen Chia, Wolfgang Janni +8 more
2022· article· en· Cancer Research· Medicine
distilled prediction:candidate · metaepi_narrowconsensus · none
13
citations
affunlabeled
Abstract OT2-11-06: SERENA-4: A Phase III comparison of AZD9833 (camizestrant) plus palbociclib, versus anastrozole plus palbociclib, for patients with ER-positive/HER2-negative advanced breast cancer who have not previously received systemic treatment for advanced disease
Fabrice André, Seock‐Ah Im, Patrick Neven, Richard D. Baird, Johannes Ettl, Matthew P. Goetz +9 more
2022· article· en· Cancer Research· Medicine
distilled prediction:candidate · metaepi_narrowconsensus · none
12
citations
affaboutunlabeled
A double-blind placebo controlled randomized phase III trial of fulvestrant and ipatasertib as treatment for advanced HER2-negative and estrogen receptor positive (ER+) breast cancer following progression on first line CDK 4/6 inhibitor and aromatase inhibitor: The CCTG/BCT MA.40/FINER study (NCT04650581).
Stephen Chia, Andrew Redfern, Jean-Pierre M. Ayoub, Haji Chalchal, Daniel Rayson, Moira Rushton +14 more
2025· article· en· Journal of Clinical Oncology· Medicine
distilled prediction:candidate · noneconsensus · none
12
citations
affvenueno abstractunlabeled
Ribociclib-associated vortex keratopathy
Ahsen Hussain
2020· article· en· Canadian Journal of Ophthalmology· Medicine
distilled prediction:candidate · insufficient_payloadconsensus · none
11
citations
affunlabeled
BYLieve: A phase II study of alpelisib (ALP) with fulvestrant (FUL) or letrozole (LET) for treatment of <i>PIK3CA</i> mutant, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2<i>–</i>) advanced breast cancer (aBC) progressing on/after cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy.
Hope S. Rugo, Giulia Bianchi, Stephen Chia, Nicholas C. Turner, Dejan Juric, William Jacot +8 more
2018· article· en· Journal of Clinical Oncology· Medicine
distilled prediction:candidate · metaepi_narrowconsensus · none
10
citations
affunlabeled
Abstract GS2-07: Updated results from a phase 3 randomized clinical trial in participants (pts) with 1-3 positive lymph nodes (LN), hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) ≤ 25 randomized to endocrine therapy (ET) +/- chemotherapy (CT): SWOG S1007 (RxPONDER)
Kevin Kalinsky, William E. Barlow, Julie R. Gralow, Funda Meric‐Bernstam, Kathy S. Albain, Daniel F. Hayes +28 more
2022· article· en· Cancer Research· Medicine
distilled prediction:candidate · metaepi_narrow+insufficient_payloadconsensus · none
10
citations
← previousnext →

How this was built: Screen · Findings · About